Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab versus bisphosphonates in children and adolescents with osteogenesis imperfecta
CTR20251536Phase 3Active
- Sponsor
- Amgen
- Start
- Aug 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of romosozumab in osteogenesis imperfecta (OI), sponsored by Amgen. Started Aug 2025; status: active.
02
Drugs
romosozumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on CTR20251536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251536.